Alphabet Chairman Hennessy Called For AI-Ethics Agreement With China

-Nikkei https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3213111/hong-kong-cruises-future-arrival-resorts-world-one-150-calls-ships-16-companies-come?module=live&pgtype=homepage

byCharles Gross

March 10, 2023

1 minute read

-Nikkei

https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3213111/hong-kong-cruises-future-arrival-resorts-world-one-150-calls-ships-16-companies-come?module=live&pgtype=homepage

Deutsche Bank Maintains Buy on Tenet Healthcare, Raises Price Target to $110

By Benzinga Newsdesk

Today, 4:32 AM

Deutsche Bank analyst Pito Chickering maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $100 to $110.

THC

Citigroup Upgrades Penumbra to Buy, Lowers Price Target to $212

By Benzinga Newsdesk

Today, 4:32 AM

Citigroup analyst Joanne Wuensch upgrades Penumbra (NYSE:PEN) from Neutral to Buy and lowers the price target from $217 to $212.

PEN

Gilead Sciences’ Can Resume Injectable Lenacapavir Trial(s) For HIV Infection

By Vandana Singh

Today, 4:32 AM

The FDA has lifted the clinical hold placed on Gilead Sciences Inc’s (NASDAQ:GILD) Investigational New Drug Application to evaluate injectable lenacapavir for…

GILD

Almost Half of Crohn’s Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie’s Risankizumab

By Vandana Singh

Today, 4:32 AM

AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.

ABBV

Alphabet Chairman Hennessy Called For AI-Ethics Agreement With China

Related Posts

Deutsche Bank Maintains Buy on Tenet Healthcare, Raises Price Target to $110

Citigroup Upgrades Penumbra to Buy, Lowers Price Target to $212

Gilead Sciences’ Can Resume Injectable Lenacapavir Trial(s) For HIV Infection

Almost Half of Crohn’s Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie’s Risankizumab